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A REVIEW OF TREATMENT PATTERNS OF PATIENTS WITH
PULMONARY ARTERIAL HYPERTENSION IN THREE EUROPEAN
COUNTRIES
Angalakuditi M1, Wright D2, Gaskin M3, Farkhoury W3
1Eli Lilly and Company, Indianapolis, IN, USA, 2IMS Health, London, UK, 3IMS Health, London, 
London, UK
OBJECTIVES: The aim of this study was to review the existing treatment patterns 
for patients diagnosed with pulmonary arterial hypertension in the UK, France and 
Germany. METHODS: IMS Disease Analyzer, a longitudinal patient database pro-
viding information from continuing physician-patient interaction on consultations, 
diagnoses and treatment within Primary Care, was used to review the treatment 
patterns for PAH patients in the UK, France and Germany over a two year period,
in order to describe: 1) different therapies used; 2) combination therapies; 3) clinical
and economic outcomes of different therapies; 4) dose and drug utilization patterns; 
and 5) resource utilization. RESULTS: In all three countries, the prevalence of 
PAH was found to increase with age, with two-thirds of PAH patients being 60 
years of age or older, with more female than male patients being diagnosed with PAH.
PAH patients were also found to have been prescribed at least one medication, with 
23% in France, 15% in Germany and 56% of patients in the UK being prescribed 
between 3 and 6 medications. In the UK, most prescriptions were found to refer to
diuretics, calcium channel blockers and anti-thrombotic agents. In France, most
prescriptions referred to beta-blockers, angiotensin receptor blockers and diuretics. In
Germany, most prescriptions referred to diuretics, calcium channel blockers and
beta blockers. For PAH patients in both France and Germany the median number of 
days receiving therapy over the 2 year period was found to be 100 days, whereas in
the UK, this ﬁ gure rose to 500 days. CONCLUSIONS: Whilst there were many simi-
larities in the sociodemographic proﬁ le of PAH patients, many differences in the
treatment patterns for patients diagnosed with PAH in the UK, France, and Germany 
were found.
PCV102
INFLUENCE OF COPAYMENT DIFFERENTIAL BETWEEN GENERIC AND 
PREFERRED BRAND PRESCRIPTIONS DRUGS ON GENERIC FILL RATE
Yuan Y1, Carlson AM2, Gleason PP3, Schommer JC4
1IMS Health, Blue Bell, PA, USA, 2Data Intelligence Consultants LLC, Eden Prairie, MN, USA, 
3Prime Therapeutics LLC, Eagan, MN, USA, 4University of Minnesota, Minneapolis, MN, USA
OBJECTIVES: To investigate the inﬂ uence of member copayment differential 
between generic and preferred brand name prescription drugs on generic ﬁ ll rate
(GFR) within two drug therapy classes (antidepressants and antihypertensive).
METHODS: This study was a retrospective observational cohort study using
individual member as the unit of analysis. The antidepressant cohort was members
who utilized an antidepressant (SSRI or SNRI). The antihypertensive cohort was 
members who had an antihypertensive claim (ACEI, ARBs, CCB, BB, and diuretics).
All 2006 claims were analyzed and adjusted to 30-day equivalents. A total of 149,359
members with age q22 years, continuously enrolled, no beneﬁ t change, with a 
ﬂ at copayment commercial beneﬁ t plan, and had at least one claim were eligible 
for analysis. Medical claims were used to calculate Charlson severity of illness
scores. A Tobit model to assess the inﬂ uence of independent variables: copayment 
differentials, age, gender, income, generic copayment, number of unique medications
taken, mail-order service use, specialty drug use, other maintenance drug use, Charlson 
score, on the GFR (dependent variable) was built for each cohort. RESULTS:
Of 149,359 members, the antidepressant cohort comprised 22,484 (15.1%) members 
with an average 5.7 30-day antidepressant claims, mean $16.40 copayment
differential, and GFR of 51.8%. For the antihypertensive cohort 33,673 (22.5%) 
members had 8.6 antihypertensive 30-day claims, mean $16.50 copayment differen-
tial, and GFR of 72.3%. Antidepressant Tobit model found the mean marginal 
effect of copayment differential on GFR was 0.005 (p  0.001) indicating a $10 
copayment differential increase is estimated to increase antidepressant GFR by
5% points. In the antihypertensive cohort, the mean marginal effect of copayment 
differential on GFR was 0.001 (p  0.001). When copayment differential increased 
by $10 the estimated GFR increased by 1% point. CONCLUSIONS: There was
a signiﬁ cant positive relationship between copayment differential and generic ﬁ ll
rate. However, the magnitude of the effect varied across different drug therapy
classes.
PCV103
ASSOCIATION BETWEEN COPAYMENT AND ADHERENCE TO STATIN 
TREATMENT IN A VETERAN POPULATION: A RETROSPECTIVE
ANALYSIS
Bounthavong M1, Kazerooni R1, Christopher MLD1, Mendes M1, Juzba M2, Plowman BK1, 
Morreale AP1
1Veterans Affairs San Diego Healthcare System (VASDHS), San Diego, CA, USA, 
2Department of Veterans Affairs (Long Beach), Long Beach, CA, USA
OBJECTIVES: This study investigated the association between copayment and
adherence to statin treatment in a veteran population at the Veterans Affairs San 
Diego Healthcare System (VASDHS). METHODS: This was a retrospective analysis
of patients initiated on statin therapy and followed for 12 months to determine 
adherence. Patients who began a statin during the period of November 2006 to 
December 2007 were included. Patients who switched statin therapy or who were 
discontinued before 12 months were excluded. Eligibility was established if patients
had at least two visits to their provider post-index date and one visit pre-index
date. Adherence was deﬁ ned as a medication possession ratio (MPR) q80%. Indepen-
dent variables included: age, gender, ethnicity, BMI, number of medications, baseline 
lipid panel, percent service connection, and comorbid conditions. Service connection 
deﬁ nes level of medical and prescription coverage beneﬁ t and awarded based on
disability, socioeconomic and military-service factors. Non-parametric continuous 
data was evaluated using the Mann Whitney-U. Categorical data was evaluated
using the Pearson Chi-squared test. Logistic regression model was used to determine 
predictors of adherence. RESULTS: A majority of the cohort (N  6890) was 
63.7 (o11.23) years old, male (95.6%), Caucasian (19.4%), taking simvastatin 
(84.6%), and had hypertension (73.0%). Statistically signiﬁ cant differences were 
seen in all variables between the adherent and nonadherent groups at baseline 
with few exceptions. Nonadherent patients had an MPR of 55% compared to adher-
ent patients MPR of 95% (p  0.0005). No difference in adherence found between
non-service connected patients and those service connected (p  0.449). Patients 
who were older (OR  1.01, 95%CI: 1.002–1.014), had higher percent service
connection (OR  1.00, 95%CI: 1.000–1.004), and high quantity of medications
(OR  1.05, 95%CI: 1.032–1.064) were more likely to be adherent. CONCLUSIONS:
Copayment had no affect on adherence. However, patients who had a higher 
percentage service connection were more likely to be adherent to their statin
medication.
PCV104
ANALYSIS OF ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS IN
THE US MEDICAID PROGRAM FROM 1991 TO 2007
Bian B1, Li X2, Jing Y3, Guo JJ2, Kelton CM2, Wigle PR2
1University of Cincinnati, Cincinnanti, OH, USA, 2University of Cincinnati, Cincinnati, OH, 
USA, 3Bristol-Myers Squibb, Plainsboro, NJ, USA
OBJECTIVES: Angiotensin-converting-enzyme (ACE) inhibitors have been widely 
used for treatment of hypertension, heart failure, diabetes mellitus and kidney disease. 
The purposes of this study was to describe the utilization and spending trends of ACE 
inhibitors and assess market-share competition between brand-name and generic drugs 
in the US Medicaid Program. METHODS: Since captopril, the 1st ACE inhibitor, 
introduced in 1981, there are 22 brand-names including 10 combination drugs are 
available in the market. Multiple generic ACE inhibitors are available including
benazepril, captopril, enalapril, fosinpril, lisinopril, moexipril, perindopril, quinapril, 
and ramipril. National Medicaid pharmacy data were extracted from CMS from 1st
quarter 1991 to 3rd quarter 2007 in order to obtain quarterly total prescription
numbers and reimbursement amounts. The per-prescription reimbursement as a proxy 
of drug price was calculated for all study ACE inhibitors. The market-shares were 
calculated based on proportion of total prescriptions numbers. RESULTS: By 2005,
the expenditure for ACE inhibitors reached to $490.5 million ($248 million for brand 
drugs and $242.5 million generic drugs). But It had been seen a sudden drop on the
utilization of both brand-name and generic ACEIs since 2006 quarter 1 because of 
implementation of Medicare PartD. The average per-prescription reimbursement for 
brand-name ACE inhibitors increased overtime from $35.2 in the ﬁ rst quarter of 1991 
to $67.1 in the third quarter of 2007, whereas per-prescription reimbursement for
generics decreased from $31.5 in 1996 to $22.4 in 2007. After the generics entry, the
market share of brand-name drugs dropped from 100% in 1991 to 12.6% in 2007.
CONCLUSIONS: Generic reimbursement prices decreased due to their competitions,
while the brand-name drug prices increased overtime regardless new entry counter-
parts. There is a dramatic competition in market share between brand-name and 
generic drugs in Medicaid program.
HT4
IN PROMETHEUS’ SHADOW: EPIDEMIOLOGICAL AND ETHICAL
PERSPECTIVES ON OUTCOMES OF CARDIOPULMONARY
RESUSCITATION
Levy A1, Koning F2, Lockey R2, Bellack N3, Christie T4, Desjardins E2
1University of British Columbia, Vancouver, BC, Canada, 2Providence Health Care, Vancouver, 
BC, Canada, 3University of Ottawa, Vancouver, BC, Canada, 4Atlantic Health Sciences
Corporation, Saint John Regional Hospital, St John, NB, Canada
OBJECTIVES: Cardiopulmonary resuscitation (CPR), a life-saving technology devel-
oped mid-20th century, was intended to prevent sudden, unexpected death. Since then, 
CPR has increasingly been performed on terminal patients with irreversible illness
treated in acute care settings. The objectives were to: synthesize the literature estimates
of survival following CPR delivered in acute care hospitals; identify predictors of sur-
vival; and contextualize the ﬁ ndings in terms of ethics of end of life care. METHODS:
We conducted a comprehensive literature review using PUBMED to identify studies 
in which survival after CPR was reported for adult patients treated in hospitals.
RESULTS: The literature yielded 130 studies reporting survival after CPR. The most 
common outcomes were return of spontaneous circulation (52% of studies, arithmetic
mean survival 43% (range 12% to 100%)) and survival to hospital discharge (64%
of studies, arithmetic mean survival 15% (range 0% to 40%)). Diagnoses with lower 
rates of survival included metastatic cancer, sepsis, renal failure, pneumonia, stroke, 
diabetes and AIDS. CONCLUSIONS: While heterogeneity in study populations and
outcomes invalidated summary estimates, all studies showed that only a minority of 
patients undergoing CPR survived even to hospital discharge. Current use of CPR in
many hospitalized patients likely does not achieve consensus goals, to: preserve life, 
restore health, and limit disability. Reviving terminally ill patients or those with major 
co morbidities should involve consideration of the efﬁ cacy, preferences of patients and
caregivers, and burdens imposed. However, unlike Prometheus who was punished for
stealing ﬁ re from Zeus and handing it to mankind, the burden of CPR is carried by
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patients undergoing CPR and by those left untreated through spent opportunity costs. 
This serves as a reminder that the technological imperative – because existing technol-
ogy means that something can be done, then this action ought to be done – must be 
thoughtfully considered by those undertaking health technology assessments.
PCV106
CREATING A QUALITY INDEX TO RANK HOSPITALS
Baser O
University of Michigan and STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: Utilize simple measures, such as mortality and hospital volume, to 
create and validate the composite quality score. Although payers are increasingly 
reporting information on hospital volume and mortality to rank hospitals, the value
of these data is uncertain. There is a need for better quality measures. METHODS:
We used Medicare Analysis Provider and Review ﬁ les for resection of pancreatic cancer
(2003–06). Using the empirical Bayes approach to combine mortality rates with
information on hospital volume at each hospital, we created an index to weight 
observed mortality according to how reliable it is estimated, with the remaining weight 
placed on hospital volume. We validated our index by a) establishing the extent to 
which it explained hospital-level variation in risk adjusted mortality rates, and b) 
determining how well it predicted future hospital performance. RESULTS: Since the 
average hospital caseload was only 6, 16% of the weight was placed on mortality and 
84% on volume. Composite measure explained the highest percentage of hospital level 
variation (54%) and predicted the largest differences in future risk adjusted mortality
across hospitals (odd ratio  3.16, p  0.000). CONCLUSIONS: Using national 
Medicare data for resection of pancreatic cancer, we found that simple composite
measure was a strong predictor of subsequent performance of the operation. In this
regard, it was more effective than individual measures. Such measures would be useful 
to help patients and payers identify low quality hospitals for major surgery.
PCV107
SPECIFICITY OF ADMINISTRATIVE DATA FOR IDENTIFYING HEART
FAILURE PATIENTS FOR HOSPITAL QUALITY PERFORMANCE
INITIATIVES
Bautista A1, Stein BD2, Lee TA3, Meltzer DO2, DiDomenico R1, Krishnan JA2, 
Schumock GT1
1University of Illinois at Chicago, Chicago, IL, USA, 2University of Chicago, Chicago, IL, USA, 
3Hines VA Hospital and Northwestern University, Chicago, IL, USA
OBJECTIVES: Administrative data are often used to identify patients for inclusion 
in quality performance measures. We examined the speciﬁ city of ICD-9 codes from
administrative data for identifying patients hospitalized for heart failure (HF).
METHODS: Charts of 90 adults (q25 years) admitted to two university hospitals
between November 2005 and October 2006 were selected on the basis of ICD-9
discharge diagnosis [primary diagnosis of HF (n  45), or without HF (n  45)]. 
The ICD-9 codes used to identify HF were those used in the Joint Commission 
National Hospital Quality Measures. Medical charts were abstracted to identify 
the physician discharge diagnoses. Speciﬁ city was calculated by comparing the
number of patients identiﬁ ed with HF via ICD-9 codes from administrative data to 
the number identiﬁ ed by medical record review [(true negatives/(true negatives 
false positives)]. The main analysis was based on the reference standard being the
physician primary discharge diagnosis of HF. In sensitivity analyses we expanded the 
deﬁ nition of the reference standard to include; A) physician secondary discharge
diagnosis of HF with shortness of breath (SOB) or respiratory failure (RF) as the 
primary diagnosis; and B) physician secondary discharge diagnosis of HF with SOB,
RF, arrhythmia, or valvular disease as the primary diagnosis. RESULTS: The speciﬁ city
of the administrative data was 75.0% (95% CI 62.1–85.3%) for the main analysis. 
Using the expanded deﬁ nitions of the reference standard A and B above, the speciﬁ city 
was 77.6 % (95% CI 64.7–87.5 %) and 81.8% (95% CI 69.1–90.9%), respectively. 
CONCLUSIONS: Administrative data have relatively high speciﬁ city (75%) for
identifying hospitalized patients with heart failure. Additional analyses are needed to
determine the extent to which quality among those captured by administrative data
reﬂ ects overall quality, and to determine the sensitivity of administrative data for 
identifying HF patients.
PCV108
USE OF RENIN SYSTEM AGENTS AMONG HYPERTENSION PATIENTS
WITH RENAL DISEASE IN A MANAED CARE SETTING
Stern L1, Lamerato L2, Ogbonnaya A1, Hwa Ong S3, Munk VC3, Charney A4
1Analytica International, New York, NY, USA, 2Henry Ford, Detroit, MI, USA, 3Novartis
Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, 
USA
OBJECTIVES: The objective of this study was to determine the likelihood of receiving 
renin system agents as the ﬁ rst HTN treatment among patients with prior renal 
disease. METHODS: This retrospective study utilized data from the Henry Ford 
Health System to identify HTN patients with renal disease who received a renin system 
agent at any time. Patients were 18 years old with a minimum of one year enrollment 
in the health plan of one year following the ﬁ rst HTN visit in the study period. The
ﬁ rst HTN treatment was characterized as monotherapy or combination therapy with
renin system agents. Logistic regression modeling determined the likelihood of receiv-
ing a renin system agent ﬁ rst line among patients diagnosed with renal disease before 
initiating HTN therapy compared to patients diagnosed with renal disease after initiat-
ing HTN therapy while adjusting for covariates. RESULTS: A total of 4,523 patients
had a diagnosis of HTN and renal disease (mean age 64 years, 50% white and 54% 
male). Approximately 58% of patients were treated with two HTN agents and 42% 
with three or more. Only 338 (7.5%) patients were diagnosed with renal disease before 
their HTN treatment. Slightly higher proportions of patients diagnosed with renal 
disease before, compared to after initiating HTN therapy (59% vs. 51% respectively),
were prescribed renin system agents ﬁ rst line. After adjusting for covariates, patients 
diagnosed with renal disease before initiating HTN therapy were not more likely to 
receive a renin system agent ﬁ rst-line compared to patients diagnosed with renal 
disease after initiating HTN therapy (OR: 0.863, 95% CI: 0.664–1.123). CONCLU-
SIONS: While all patients received renin system agents, those with prior renal disease 
were not more likely to receive this treatment ﬁ rst line suggesting an opportunity to
optimize treatment for renal patients with medications that block the Renin-Angio-
tensin-Aldosterone System.
PCV109
THERAPY INTERRUPTIONS IN PATIENTS SWITCHED FROM BRANDED
TO OTHER GENERIC STATINS
Chapman RH1, Benner JS1, Girase P2, Benigno M3, Axelsen KJ3, Liu L3, Nichol MB4
1IMS Health, Falls Church, VA, USA, 2IMS Health, Watertown, MA, USA, 3Pﬁ zer 
Pharmaceuticals, New York, NY, USA, 4University of Southern California, Los Angeles, CA, 
USA
OBJECTIVES: To compare dose-equivalence, adherence and subsequent switch
rates among patients recently switched from a branded to generic version of the 
same statin (generic substitution, GS) vs. those switched from branded statin to 
generic version of a different statin (therapeutic substitution, TS). METHODS: In a 
retrospective cohort analysis among adult enrollees in ^90 US health plans, we identi-
ﬁ ed adult patients who switched from a branded to generic statin from July-December
2006. Patients were classiﬁ ed by type of statin switch: GS (eg, branded simvastatin 
nú generic simvastatin), and TS (eg, branded atorvastatin nú simvastatin). Demo-
graphic and clinical data were collected from claims before switch through six
months follow-up. Outcomes of interest included proportion of patients that
switched to a less potent daily dose, that switched back to the previous branded 
statin after switch, and that were at least 80% adherent during the 6 months after
initial switch. Signiﬁ cant predictors of each clinical outcome were identiﬁ ed using 
multivariable logistic regression models, adjusting for differences between groups in 
covariates and potential confounders. RESULTS: The TS (n  3,807) and GS (n 
40,165) groups were generally similar demographically, although TS was more fre-
quent in HMO health plans than GS (40.6% vs. 33.7%, p  .001), and less likely in 
POS plan patients (9.2% vs. 16.6%). Compared to GS, TS patients were more likely
to be switched to a less potent dose (26.2 % vs. 0.5%); less likely to be adherent 
(70.2% vs. 79.5%); and more likely to switch back to the previous branded statin 
(11.3% vs. 2.9%, p  .001 for all). These effects remained signiﬁ cant in the regression 
models adjusting for demographic and baseline clinical characteristics. CONCLU-
SIONS: TS is more likely to involve a subsequent disruption to statin therapy than
GS. TS could potentially lead to adverse impacts on patients’ outcomes, and should 
be studied further.
PCV110
DO CANADIAN PHYSICIANS CORRECTLY IDENTIFY HIGH RISK CV
PATIENTS?
Beamer B, Liovas A
AstraZeneca, Mississauga, ON, Canada
OBJECTIVES: Under estimating CV risk levels of patients may lead to inappropriate 
care and unintended clinical and economic consequences. It is not known to what
extent Canadian physicians correctly identify the CV risk level of patients who have
had previous CV events and/or a diagnosis of diabetes mellitus. METHODS: A total 
of 431 General Practioners from across Canada collected pre-speciﬁ ed data on a case 
record form (CRF) for CV patients during routine ofﬁ ce visits between June 2007 and 
December 2007. Physicians were asked to assess the risk level of each patient during
the completion of the CRF. Patients for whom the physician reported a diagnosis of 
diabetes mellitus (DM) and/or who had a previous history of myocardial infarction 
(MI), stroke (S), or peripheral artery disease (PAD) were extracted. Physician assessed 
risk levels were then compared to this subset of commonly accepted high-risk patients.
RESULTS: Data on 14,982 patients was obtained. A total of 2822 had a previous 
history of MI, S, or PAD. Physicians correctly assessed 2540 (90.0%) as high risk, 
however differences were observed between provinces: BC 81.5%, AB 86.9%, QC 
92.9%, ON 90.3%, NS 90.9%, NB 85.3%. A further 1850 had DM and a previous
history of MI, S, or PAD. Physicians correctly assessed 1778 (96.1%) as high risk, 
however regional differences were observed: BC 87.5%, AB 89.6%, QC 98.5%, ON
97.0%, NS 94.4%, NB 97.7%. CONCLUSIONS: Despite agreement that patients 
with a previous history of MI, S, or PAD should be viewed as high risk, and that those 
with DM and a previous history of MI, S, or PAD are high risk, some physicians still
under estimate the CV risk. The reasons for this under assessment and the unintended
clinical and economic consequence need to be explored further.
